A phase I open-label dose-escalation study to investigate the safety pharmacokinetics pharmacodynamics and clinical activity of GSK3368715 in participants with solid tumors and DLBCL

Brief description of study

The purpose of this study is to test the safety, tolerability, and effectiveness of GSK3368715 (called the study drug from now on) for solid tumors and DLBCL. We want to find out what effects, good or bad, the study drug has on you and your cancer. This is an investigational study of a drug named GSK3368715, which means it is still being tested and is not approved by the US Food and Drug Administration (FDA) as a routine therapy.


Clinical Study Identifier: s18-00837
ClinicalTrials.gov Identifier: NCT03666988
Principal Investigator: Daniel C Cho.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.